CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities
Net income (loss)	$ 882,494	$ (167,392)
Less: Net income from discontinued operations	(961,062)	(39,864)
Net loss from continuing operations	(78,568)	(207,256)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,057	4,551
Amortization and accretion income, net	(342)	9
Ampreloxetine interest accretion	424
Share-based compensation	32,784	45,143
Gain on disposal of property and equipment	(96)
Gain on sale of Velusetrag	(2,709)
Amortization of right-of-use assets	2,284	2,758
Gain from lease modification		(1,863)
Loss on extinguishment of debt	3,034
Other		35
Changes in operating assets and liabilities:
Receivables from collaborative and licensing arrangements	(49)	1,867
Prepaid clinical and development services	7,600	7,132
Other prepaid and current assets	(1,148)	(99)
Right-of-use lease assets	(2,587)
Other assets	(1,743)	(1,006)
Accounts payable	2,150	2,206
Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities	(18,465)	(36,573)
Accrued interest payable	(1,246)
Deferred revenue	(186)	(8,648)
Operating lease liabilities	(1,111)	443
Other long-term liabilities	(421)	776
Net cash used in operating activities - continuing operations	(57,338)	(190,525)
Net cash used in operating activities - discontinued operations	(5,598)	25,101
Net cash used in operating activities	(62,936)	(165,424)
Investing activities
Purchases of property and equipment	(306)	(2,962)
Purchases of marketable securities	(93,260)	(104,774)
Maturities of marketable securities	108,700	221,400
Sale of short-term investments and marketable securities	5
Proceeds from the sale of Velusetrag	2,709
Proceeds from the sale of property and equipment	1,866	6
Net cash provided by investing activities - continuing operations	19,714	113,670
Net cash provided by investing activities - discontinued operations	1,095,134
Net cash provided by investing activities	1,114,848	113,670
Financing activities
Proceeds from the sale of ordinary shares, net		108,180
Repurchases of ordinary shares	(94,037)
Proceeds from ampreloxetine funding, net	24,464
Proceeds from ESPP purchases	488	2,862
Proceeds from option exercises		5
Repurchase of shares to satisfy tax withholding	(2,457)	(8,606)
Net cash (used in) provided by financing activities - continuing operations	(703,145)	91,711
Net cash used in financing activities - discontinued operations	(20,189)
Net cash (used in) provided by financing activities	(723,334)	91,711
Net increase in cash, cash equivalents, and restricted cash	328,578	39,957
Cash, cash equivalents, and restricted cash at beginning of period	90,796	82,300
Cash, cash equivalents, and restricted cash at end of period	419,374	122,257
Supplemental disclosure of cash flow information
Cash paid for interest	22,244	26,954
Cash paid (received) for income taxes, net	26	(3,814)
2035 notes
Financing activities
Principal payment on notes	(399,998)	$ (10,730)
2033 notes
Financing activities
Principal payment on notes	$ (231,605)